1 Yuen, K.-S., Ye, Z.-W., Fung, S.-Y., Chan, C.-P. & Jin, D.-Y. SARS-CoV-2 and COVID-19: The most important research questions. Cell Biosci 10, 40-40, doi:10.1186/s13578-020-00404-4 (2020).
2 Lee, S. et al. Clinical Course and Molecular Viral Shedding Among Asymptomatic and Symptomatic Patients With SARS-CoV-2 Infection in a Community Treatment Center in the Republic of Korea. JAMA Internal Medicine, doi:10.1001/jamainternmed.2020.3862 (2020).
3 Chan, J. F. et al. Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease. Clin Microbiol Rev 28, 465-522, doi:10.1128/CMR.00102-14 (2015).
4 Cheng, V. C., Lau, S. K., Woo, P. C. & Yuen, K. Y. Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection. Clin Microbiol Rev 20, 660-694, doi:10.1128/CMR.00023-07 (2007).
5 de Wit, E., van Doremalen, N., Falzarano, D. & Munster, V. J. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol 14, 523-534, doi:10.1038/nrmicro.2016.81 (2016).
6 Sheahan, T. P. et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med 9, doi:10.1126/scitranslmed.aal3653 (2017).
7 Beigel, J. H. et al. Remdesivir for the Treatment of Covid-19 - Preliminary Report. N Engl J Med, doi:10.1056/NEJMoa2007764 (2020).
8 Wang, Y. et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 395, 1569-1578, doi:10.1016/S0140-6736(20)31022-9 (2020).
9 Goldman, J. D. et al. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. N Engl J Med, doi:10.1056/NEJMoa2015301 (2020).
10 Hung, I. F. et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet 395, 1695-1704, doi:10.1016/S0140-6736(20)31042-4 (2020).
11 Riva, L. et al. A Large-scale Drug Repositioning Survey for SARS-CoV-2 Antivirals. bioRxiv, doi:10.1101/2020.04.16.044016 (2020).
12 Gopal, M., Padayatchi, N., Metcalfe, J. Z. & O'Donnell, M. R. Systematic review of clofazimine for the treatment of drug-resistant tuberculosis. Int J Tuberc Lung Dis 17, 1001-1007, doi:10.5588/ijtld.12.0144 (2013).
13 Nix, D. E. et al. Pharmacokinetics and relative bioavailability of clofazimine in relation to food, orange juice and antacid. Tuberculosis (Edinb) 84, 365-373, doi:10.1016/j.tube.2004.04.001 (2004).
14 Kissler, S. M., Tedijanto, C., Goldstein, E., Grad, Y. H. & Lipsitch, M. Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period. Science 368, 860-868, doi:10.1126/science.abb5793 (2020).
15 Riva, L. et al. Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing. Nature, doi:10.1038/s41586-020-2577-1 (2020).
16 Sharma, A. et al. Human iPSC-Derived Cardiomyocytes Are Susceptible to SARS-CoV-2 Infection. Cell Rep Med 1, 100052-100052, doi:10.1016/j.xcrm.2020.100052 (2020).
17 Bastard, P. et al. Auto-antibodies against type I IFNs in patients with life-threatening COVID-19. Science, eabd4585, doi:10.1126/science.abd4585 (2020).
18 Zhang, Q. et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science, eabd4570, doi:10.1126/science.abd4570 (2020).
19 Hadjadj, J. et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science 369, 718-724, doi:10.1126/science.abc6027 (2020).
20 Feng, P. C., Fenselau, C. C. & Jacobson, R. R. Metabolism of clofazimine in leprosy patients. Drug Metab Dispos 9, 521-524 (1981).
21 Yoon, G. S. et al. Clofazimine Biocrystal Accumulation in Macrophages Upregulates Interleukin 1 Receptor Antagonist Production To Induce a Systemic Anti-Inflammatory State. Antimicrob Agents Chemother 60, 3470-3479, doi:10.1128/AAC.00265-16 (2016).
22 Chan, J. F. et al. Simulation of the clinical and pathological manifestations of Coronavirus Disease 2019 (COVID-19) in golden Syrian hamster model: implications for disease pathogenesis and transmissibility. Clin Infect Dis, doi:10.1093/cid/ciaa325 (2020).
23 Ulhaq, Z. S. & Soraya, G. V. Interleukin-6 as a potential biomarker of COVID-19 progression. Med Mal Infect 50, 382-383, doi:10.1016/j.medmal.2020.04.002 (2020).
24 Cholo, M. C., Steel, H. C., Fourie, P. B., Germishuizen, W. A. & Anderson, R. Clofazimine: current status and future prospects. J Antimicrob Chemother 67, 290-298, doi:10.1093/jac/dkr444 (2012).
25 Herold, T. et al. Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19. J Allergy Clin Immunol 146, 128-136 e124, doi:10.1016/j.jaci.2020.05.008 (2020).
26 Hwang, T. J. et al. Safety and availability of clofazimine in the treatment of multidrug and extensively drug-resistant tuberculosis: analysis of published guidance and meta-analysis of cohort studies. BMJ Open 4, e004143-e004143, doi:10.1136/bmjopen-2013-004143 (2014).
27 Sangana, R., Gu, H., Chun, D. Y. & Einolf, H. J. Evaluation of Clinical Drug Interaction Potential of Clofazimine Using Static and Dynamic Modeling Approaches. Drug Metabolism and Disposition 46, 26-32, doi:10.1124/dmd.117.077834 (2018).
28 Falzon, D. et al. World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update. Eur Respir J 49, doi:10.1183/13993003.02308-2016 (2017).
29 Tang, S. et al. Clofazimine for the treatment of multidrug-resistant tuberculosis: prospective, multicenter, randomized controlled study in China. Clin Infect Dis 60, 1361-1367, doi:10.1093/cid/civ027 (2015).
30 Dalcolmo, M. et al. Effectiveness and safety of clofazimine in multidrug-resistant tuberculosis: a nationwide report from Brazil. Eur Respir J 49, doi:10.1183/13993003.02445-2016 (2017).
31 Baik, J. & Rosania, G. R. Molecular imaging of intracellular drug-membrane aggregate formation. Mol Pharm 8, 1742-1749, doi:10.1021/mp200101b (2011).
32 Morrison, N. E. & Marley, G. M. The mode of action of clofazimine DNA binding studies. International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association 44, 133-134 (1976).
33 Lucas, C. et al. Longitudinal analyses reveal immunological misfiring in severe COVID-19. Nature 584, 463-469, doi:10.1038/s41586-020-2588-y (2020).
34 Ren, Y. R. et al. Clofazimine Inhibits Human Kv1.3 Potassium Channel by Perturbing Calcium Oscillation in T Lymphocytes. PLOS ONE 3, e4009, doi:10.1371/journal.pone.0004009 (2008).
35 <https://www.gilead.com/news-and-press/press-room/press-releases/2020/6/an-open-letter-from-daniel-oday-chairman--ceo-gilead-sciences> (2020).
36 Weng, Z. et al. A simple, cost-effective but highly efficient system for deriving ventricular cardiomyocytes from human pluripotent stem cells. Stem Cells Dev 23, 1704-1716, doi:10.1089/scd.2013.0509 (2014).
37 Yuan, S. et al. SREBP-dependent lipidomic reprogramming as a broad-spectrum antiviral target. Nature Communications 10, 120, doi:10.1038/s41467-018-08015-x (2019).
38 Chu, H. et al. Comparative replication and immune activation profiles of SARS-CoV-2 and SARS-CoV in human lungs: an ex vivo study with implications for the pathogenesis of COVID-19. Clin Infect Dis, doi:10.1093/cid/ciaa410 (2020).
39 Zhang, A. J. et al. SARS-CoV-2 infects and damages the mature and immature olfactory sensory neurons of hamsters. Clin Infect Dis, doi:10.1093/cid/ciaa995 (2020).
40 To, K. K. et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect Dis 20, 565-574, doi:10.1016/S1473-3099(20)30196-1 (2020).
41 Kim, D. et al. TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol 14, R36, doi:10.1186/gb-2013-14-4-r36 (2013).
42 Liao, Y., Smyth, G. K. & Shi, W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 30, 923-930, doi:10.1093/bioinformatics/btt656 (2014).
43 Yu, G., Wang, L. G., Han, Y. & He, Q. Y. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS 16, 284-287, doi:10.1089/omi.2011.0118 (2012).
44 Shannon, P. et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 13, 2498-2504, doi:10.1101/gr.1239303 (2003).
45 Hoffmann, M. et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell 181, 271-280.e278, doi:https://doi.org/10.1016/j.cell.2020.02.052 (2020).
46 Xie, X. et al. An Infectious cDNA Clone of SARS-CoV-2. Cell Host & Microbe 27, 841-848.e843, doi:https://doi.org/10.1016/j.chom.2020.04.004 (2020).
47 Riva, L. et al. Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing. Nature, doi:10.1038/s41586-020-2577-1 (2020).
48 Ianevski, A., Giri, A. K. & Aittokallio, T. SynergyFinder 2.0: visual analytics of multi-drug combination synergies. Nucleic Acids Research 48, W488-W493, doi:10.1093/nar/gkaa216 (2020).